Nilotinib Powder
- Product Name:4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester
- CAS No.：917392-54-2
- MF: C18H16N4O2
- Assay:99%
- Appearance: Pale-yellow solid
- Molecular Weight: 320.35
- Our Packing: 25kg/barrel, 10kg/25kg/Carton, 1kg/5kg/10kg/bag or your request
Product Details
Nilotinib powder is a second-generation, next-generation targeted drug developed and sold by Novartis in Switzerland for the treatment of chronic myeloid leukemia. Raw powder antiacncer nilotinib powder, methyl 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzoate is a key intermediate of the chemotherapeutic drug nilotinib. The drug is safe and effective in the treatment of chronic myeloid leukemia/chronic myeloid leukemia patients taking imatinib for drug resistance. It is a tyrosine kinase inhibitor, and its content mainly inhibits BCR-ABL, KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB, MAPK11, ZAK kinases, etc. Dashina (nilotinib) is a new type of targeted tumor therapy drug, which has a significant effect on chronic myeloid leukemia (CML) patients who are resistant or intolerant to Gleevec (imatinib).
Health Benefits
Nilotinib is a first-line oral targeted therapy for the treatment of chronic myeloid leukemia/chronic myeloid leukemia (CML).
- Treatment of newly diagnosed Philadelphia chromosome positive (Ph+) adult chronic myeloid leukemia in the chronic phase.
- Treatment of Philadelphia chromosome-positive chronic myeloid leukemia in blast phase and accelerated phase.
- Treatment of chronic myeloid leukemia in the chronic phase that has been treated with interferon Chemicalbook.
- Children with chronic myeloid leukemia who have relapsed after myelosuppression or who are ineffective in interferon therapy.
- Treatment of KIT(CD117)-positive inoperable or metastatic malignant gastrointestinal stromal tumors.
* This statement for educational purposes only. It has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
